BST2 and neoplasm: Taken together, our findings identify CD317 as a key proteostasis regulator through coordinating the cooperation of the proteasome and autophagy in tumor cells, providing a potential target for overcoming PIs resistance or developing more effective proteostasis-targeting drugs.